Life Sciences Archive » January, 2016

Life Sciences - January, 2016

339 articles

• 5 Firms To Guide 1st Wave Of 2016 IPOs Led By Biotechs
• Shkreli Defeat Points To Complicity Of Kaye Scholer Atty
• PTAB To Review Cubicin Patents Challenged By Fresenius
• KaloBios Trustee Protests Hiring Of Morris Nichols
• 4th Circ. Says FCA Bars Suit Based On Lawyer's Knowledge
• Indivior Fights For Sales Docs In Product-Hopping Case
• Fed. Circ. Backs PTAB's Nixing Of Illumina DNA Patent Claims
• Becton Shakes Hospital's Antitrust Suit Over Syringes
• 31 Accutane Suits Tossed After Docs Would Prescribe It Again
• The FDA's Priority List For 2016
• Expectation Damages Now A Real Possibility In Delaware
• Ala. Pharmacists To Admit Guilt In Fatal Compounding Case
• Pa. Court Urged To Extend Time Bar For Risperdal Suits
• SIGA Shareholder Blasts Ch. 11 Plan Over Creditor Treatment
• Wright Medical Says $11M Hip Implant Verdict Has To Go
• Mass. Drugmaker Sued After Antibiotic Fails, Shares Tank
• Drug Provider Tells 7th Circ. W.Va. 'Pill Mill' Suit Is Covered
• AAI Warns FTC Of Impact Of Teva's $40.5B Generics Deal
• Spectrum, Investors Get Preliminary OK Of $7M Settlement
• AIA Petition In Generic Zomig Case Is Time-Barred, PTAB Says
• The Precision Medicine Initiative's 1st Annual Checkup
• Cicero On Legal Advocacy
• CVS Escapes Vitamin E False Labeling Suit
• Real Estate Rumors: Hardesty & Hanover, Whole Foods, Sanofi
• ITC Seeks Full Fed Circ. Review Of Data-Blocking Authority
• Shkreli Emails To Kaye Scholer Atty Not Privileged: Judge
• WARF Wins Kidney Disease Treatment Royalty Battle
• Theranos Posed 'Immediate Jeopardy' To Patients, Feds Say
• Sen. Vows Filibuster Of FDA Nominee Over Big Pharma Ties
• Jones Day Snags Trio Of IP Attys From MoFo, Ropes & Gray
• Eli Lilly Says Canada Skewing Facts In $354M IP Arbitration
• KaloBios Says Proposed Bonuses Won't Go To Shkreli
• Thompson Hine Adds 2 Business Litigation Vets In NY
• Baxter Keeps Trade Secret Claims In HQ Arrhythmia Drug Suit
• Surgery Center Can Shield Some Info In Meningitis MDL
• Transportation Finance Lawyer Goes To King & Spalding
• Pa. Appeals Court Urged To Toss $3M Topamax Verdict
• Mass. AG Targets Gilead Over Hep C Drug Prices
• Shire Expert Opinions Draw Fire In Adderall Antitrust Suit
• 9th Circ. Raises The Bar For Crime-Fraud Exception
• 4 Ways To Improve The Business Intake Process
• 10 Global Challenges For Life Sciences Cos. In 2016
• Supplement Maker Calls Insurer's Challenges Premature
• Boston Scientific Counterfeit Mesh Material Row Sent To FDA
• Supreme Court Again Clarifies Standards For ERISA Claims
• Gilead Hit With Suit In HIV Drug Patent Manipulation Row
• Otsuka Sues Orchid Pharma to Halt Generic Abilify
• SEC Hits Penny Stock Trader For Registration Violations
• Medical Device Co. Tactile Systems Files For $86M IPO
• Vorys Adds IP Partner From Floundering Novak Druce
• Jury Deadlocks In Tylenol Death Retrial Against J&J Unit
• Nelson Mullins Adds Ex-Hollingsworth Pharma Pro
• FDA Warning Wire: Chernobyl, Rogue Rice, Device Lapses
• 3rd Circ. Stays Provigil Pay-For-Delay Trial During Cert. Appeal
• Sanders Places Hold On FDA Nominee Over Big Pharma Ties
• Merck Hit With Patent Suit Over Cancer Drug Keytruda
• Feds Say SEC Suit Should Wait For Shkreli's Criminal Case
• Mass. Hospital Operator Seeks To Duck Rival's Monopoly Suit
• Lawmakers, Cos. Back Fed. Circ. Enhanced Damages Test
• Greatbatch Wins $37.5M In AVX Patent Trial
• Examining Recent Corporate Integrity Agreement Trends
• Justices' Amgen Order Cements High Bar For ERISA Suits
• J&J Unit Owes $20M For Child's Tylenol Death, Jury Told
• NJ Mayor Jumps From Wilentz Goldman To Locks Law Firm
• Jury Awards Thermometer Co. $14.6M In Patent Fight
• 5th Circ. Grants Jailed ArthroCare Executives New Trial
• Lialda Patent Dispute Seeks Definition In Second Trial
• Sen. Holds Up FDA Nominee, Wants Fix For Opioid Approvals
• Morrison Cohen Nabs Venable Deals Pro To Grow Corp. Team
• Millennium Sues Wockhardt Over Generic Cancer Drug
• $37.5M Greatbatch-AVX Patent Fight Goes To Jury
• Editas Joins Biotechs Braving Sluggish IPO Market
• Baxter Must Give Brokerage Firm Docs To German Insurer
• FTC Probing Turing For Antitrust Violations, Shkreli Says
• 23andMe Says Exemption Doesn't Apply In DNA Test Actions
• 2nd J&J Pelvic Mesh Trial Kicks Off In Philly
• Investor Says HeartWare Lied About FDA Compliance
• Barnes & Thornburg Adds 2 Pharma IP Pros To Minn. Office
• High Court Sends Amgen ERISA Suit Back To 9th Circ. Again
• Merger Investigations Set Records In 2015
• St. Jude Hit With Class I Recall By FDA Over Faulty Devices
• Drug Buyers Must Play Nice At Trial, Provigil Judge Says
• J&J Can't Dodge Levaquin Side-Effect Suit For Tardy Filing
• Baxter Gets OK On $42.5M Deal In Securities Fraud Suit
• Judge Won't Toss Birth Defect Claims In Zofran MDL
• GSK Asks 3rd Circ. For Atty Fees For Late Thalidomide Suit
• Judge Threatens 'Severe' Sanctions In Xyrem IP Fight
• Taxation With Representation: Cravath, Skadden, Locke Lord
• 3 Traits Of Best-In-Class General Counsel
• Fed. Circ. Denies Longer Patent Term For Pfizer Cancer Drug
• Info Still Privileged If Atty Worked As Chemist, Idenix Says
• Pharma Co.'s Arbitration Bid Denied In $6M Contract Row
• UK Pharma Firm Concealed Poor Controls, Suit Claims
• Who's To Blame For 'Superbug' Outbreak And What's Next
• Acadia Shareholder's Suit Ends In $15.75M Deal
• Attorneys Not Giving Up On IPO Work Despite Jitters
• Shkreli, Lawmakers Spar Over Drug Price Testimony
• Acorda Strikes Patent Deal To Delay Par's Generic Ampyra
• Johnson Matthey Escapes Shire's Vyvanse Patent Suit
• Stem Cell Letter Could Signal New FDA Enforcement Trend
• 'Old School' Tools May Hinder Attorney Collaboration
• Solicitor General Wants In On High Court Patent Damages Row
• Hagens Berman Asks 3rd Circ. To Allow Thalidomide Suit
• AIPLA Urges Fed. Circ. To Update On-Sale Bar Rules
• Stem Cell Co. Hit With Class Action Over Board Rules
• Abingworth Raises $105M For Life Sciences Co-Development
• Calif. Mom Says Ill. Case Keeps Her J&J False Ad Suit Alive
• Apotex Exits Forest's Patent Suit Over Generic Savella
• Baxalta Investor Seeks To Halt $32B Shire Deal
• Allergan Loses IP Suit Accusing Venture Fund Of Extortion
• Privacy May Trump Free Speech In Anti-Abortion Video Suit
• NC Jury Sees Willful Infringement Of X-Ray Patent
• Del. Justices Ax Suit Over Failed AbbVie-Shire Merger
• Shkreli Called Before Congress To Talk Drug Price Hike
• GSK Scientists Charged With Plot To Sell Secrets In China
• Paul Weiss, Kirkland, Munger Vets Launch Trial Boutique
• Hogan Lovells Boosts IP Team With Duo From King & Spalding
• J&J Unit's Expert Slams Tylenol Death Timeline At Retrial
• Consumers Fight For Class Certification In Adderall Suit
• Hogan Nabs Prominent Trial Lawyer From FaegreBD
• 6 Types Of Legal 'Mumbo-Jumbo' Attorneys Must Avoid
• FDA Chides Hospira Over 'Misleading' YouTube Ad
• Deals Rumor Mill: Ashland, Banco Popular, BNP Paribas
• Fed. Circ. Affirms PTAB Ruling Axing Glucose-Testing Patent
• Gilead Says Idenix Can't Hide Docs Behind Atty-Chemist
• Manufacturer Holding Generic Lexapro 'Hostage,' Suit Claims
• FTC, Maine Accuse Weight Loss Cos. Of Marketing Scam
• DEA Says Wis. Tribe Can't Sue To Grow Hemp
• How Analytics Can Inform Early Strategy In Patent Cases
• GlaxoSmithKline Win Leaves Only One Avandia Injury Claim
• Cryolab Hosting Ted Williams' Remains Appeals Libel Suit
• Senate Panel Splits Approach To 21st Century Cures
• Cozen's Employment Co-Chairman Joins Drinker Biddle
• Supplement Buyer Class Based On Conjecture, Justices Told
• Express Scripts Tried To Shutter Small Pharmacies, Suit Says
• FDA Warning Wire: New Woes For Wockhardt
• High Court Nixes Boehringer's Appeal In FTC Doc Row
• High Court Refuses To Reinstate $15M Alps South Patent Win
• Justices Say Medtronic IP Suit Needs 2nd Look After Commil
• Lerner David Nabs Polsinelli Life Sciences & Patent Expert
• High Court Urged To Keep Fed. Circ. Enhanced Damages Test
• J&J Says Consumer In False Ad Suit Never Bought Product
• High Court Won't Hear J&J Appeal Of $140M Motrin Verdict
• 5 Insights From Sharp Electronics Deputy GC Deborah Tyler
• Indicted Pharma Exec Shkreli Dumps Arnold & Porter
• 1 Year Later, Teva Providing Less Certainty Than Expected
• Teva, Ex-Atty Settle Wrongful Firing Suit Prior To Trial
• Tylenol Victim Showed Signs Of Bacteria, Doctor Testifies
• New Del. Rule Not For OKing Future Actions, Judge Says
• Dow Can't Shake $456M Plant Patent Arbitration Loss
• Girardi Keese Urges Justices To Hear $10M Avandia Fee Fight
• MSCs In California Mass Tort Litigation: A Call For Reform
• Market Volatility Cools Attys' Hopes For 'JPMorgan Bounce'
• Fraud, Injunction Bids In Anti-Aging Products Suit Nixed
• KaloBios Creditors Ease Demands After Shkreli Pulls Back
• Ranbaxy Can't Split Antitrust Claims From Provigil Trial
• Ohio Sec. Of State Accused Of Holding Up Drug-Pricing Law
• Bayer Wins Dismissal Of 4 NJ Mirena Suits Filed Too Late
• FDA Details Cybersecurity Steps For Approved Med. Devices
• FDA Clears Redesigned Scopes In 'Superbug' Saga
• Ex-Va. Gov.'s Bribery Appeal Heads To Supreme Court
• Weak Trial Evidence Leads To Breg Pain Pump Suit Dismissal
• Deals Rumor Mill: Asahi Group, ChemChina, Sharp Corp.
• Track & Field Officials Accused Of Criminal Doping Plot
• Colo. Pot Credit Union Takes Key Account Suit To 10th Circ.
• Bard Loses Appeal Of $2M Pelvic Mesh Verdict At 4th Circ.
• Jazz's Xyrem Patent Cases Consolidated In NJ Fed Court
• Merck Pays $830M To End Investor Suit Over Vioxx Marketing
• Hospital Can't Revive 2 Meningitis MDL Bellwether Cases
• Boston Scientific Used Counterfeit Materials, RICO Suit Says
• PTAB Rejects Amgen's Bid For Humira Patent Reviews
• Fed. Circ. Vacates Re-Exam Ruling After Patent Expires
• Novartis, Actavis Settle Patent Infringement Suit
• Liberty Fights $3M Coverage For MusclePharm SEC Probe
• Deals Rumor Mill: Pfizer, EDF, Parques Reunidos
• Abilify User Says Drug Made Him Compulsively Gamble
• Sentence Reduced For MLB Doping Scandal Ringleader
• FDA's Post-Approval Drug Tracking Not Reliable, GAO Says
• No Need To Split Provigil Claims Before Trial, Cephalon Says
• Pharma Execs Banned From Leading Drug Cos. In Insider Case
• 5 Reasons High Court Should Not Take Bob McDonnell's Case
• In-NO-vation: Patentable Subject Matter In The Courts
• Tylenol Victim's Expert Concedes Killer Bacteria Not Found
• Jury Finds X-Ray Cos. Infringed Transformer Patent
• Gilead Can't Touch Attorney's Work In Merck Patent Suit
• J&J Moves Suit Over Children's Motrin Back To Federal Court
• PTAB Says It Wrongly Denied AIA Review In Pacemaker Case
• Report Says FDA, Device Makers Failed In Superbug Outbreak
• NJ Judge Stays Dr. Reddy's Purple Pill Suit Pending Appeal
• Eli Lilly Shakes Female Sales Reps' Bias Row At 3rd Circ.
• FedEx Says Most Illegal Drug Shipping Charges Outdated
• Fed. Circ. Says Same PTAB Panel Can Begin, End AIA Reviews
• Reckitt Benckiser Accuses Invoice Auditors Of Puffed-Up Fees
• Del. Justices Grill AbbVie Investors In Shire Docs Fight
• FTC Finds Major Drop In Possible Pay-For-Delay Deals
• On-Sale Bar Applies In Angiomax Dispute, Fed. Circ. Told
• Fed. Circ. Backs Pfizer's Patent For Cancer Drug Sutent
• Hyland's Faces 2nd Suit Over Homeopathic Baby Products
• Sidley Austin Nabs Veteran FDA Device Regulator
• Abbott Asks For Reconsideration To End Stent FCA Suit
• 2015's Most Complex Deals And The Firms That Led Them
• FTC Citing Bad Data In Telemarketing Fight, Lifewatch Says
• Congress' Conflicting Approach Toward Medical Marijuana
• Drug Licensees Subject To Federal Price Regulation In Canada
• BigLaw 2016: A Look Ahead
• KaloBios Judge Freezes $5.4M Over Investor Lawsuit
• J&J Unit Knew Fatal Tylenol Tainted, Jury Hears At Retrial
• Mirena Suit's Timeliness Hinges On NJ Ruling, Judge Told
• Takeda's Gout Drug IP Case Paused After Deal With Watson
• Tough PTAB Fight Ahead For Breakthrough Gene-Editing Tech
• Roquette Gets IP Arbitration Row Paused For Appeal
• Nixon Peabody OK'd As Adviser In Taylor-Wharton Ch. 11
• FDA Warning Wire: China Drugmaker Accused Of Data Deceit
• Ex-Agriculture Official Returns To Armstrong Teasdale
• Takeda Execs Admitted To Actos Scheme, Relator Claims
• Quest Diagnostics Hit With FLSA Wages Action
• Nasdaq Suspends KaloBios After Shkreli Arrest
• Reed Smith Atty's Widow, GSK Headed To Trial In Suicide Suit
• Top 10 Antitrust Developments And Trends To Watch This Year
• Fresenius Targets Post-Warning Claims In Dialysis Drug MDL
• FDA One Step Closer To New Chief After Senate Panel Vote
• Wyeth's 'Clear Evidence' Language: Clearly Misunderstood
• AVX And Greatbatch Face Off In Pacemaker Patent Trial
• Roquette Wants IP Arbitration Row Paused During Appeal
• Ill. Court Flips Insurer's Win In Chemical Mislabeling Suit
• NJ Doc's Patent Lawsuit Sunk By No-Sue Agreement
• Gerber Formula Buyers Near Cert. In Allergy False Ad Suit
• Aggrenox Judge Questions Need For Broad Market Discovery
• Apotex Doesn't Infringe Patent For Benicar, Judge Says
• How 5 Firms Forged Separate Paths To Shire, Baxalta Deal
• FDA Forbade Fosamax Warnings, Merck Tells 3rd Circ.
• Red-Hot Pharma Space Produces 2016's First Megadeal
• High Court Stays Out Of CAFA Dismissal Fight
• Orrick Gets 4-Atty IP Team From Struggling Kenyon & Kenyon
• Travelers Needn't Defend KFx In Patent Row, 9th Circ. Affirms
• Wachtell, Davis Polk Guide Thermo Fisher's Affymetrix Buy
• Judge Rips Plaintiffs' Attorney On Essure Pleadings
• Justices Turn Down Medtronic Infuse Preemption Appeal
• Chamber Details TPP Shortcomings On Patents, Data Flows
• High Court Won't Eye Risperdal Verdict Against J&J Unit
• Top FDA Developments Of 2015 And Predictions For 2016
• Inversions: Recent Developments And 2 Predictions
• Shire Inks $32B Deal For Baxalta
• Deal Makers Hope JPMorgan Conference Will Perk Up Biotechs
• Taylor-Wharton Defends Bid To Retain Nixon Peabody
• Life Sciences Group Of The Year: Wilson Sonsini
• Embezzling Ex-Pharma Manager In NJ Gets 5 Years
• P&G Asks Supreme Court To Nix Probiotic 'Snake Oil' Class
• Glenmark Tells Fed. Circ. Bayer Fell Short In Finacea IP Suit
• Bad Test Used For Pfizer Cancer Drug Patent, Fed. Circ. Told
• J&J Urges Appeals Court To Uphold Philly Risperdal Win
• Obama Vetoes Latest Attempt To Dismantle ACA
• Deals Rumor Mill: Time Warner, Simcere Pharma, Philips
• 3rd Circ. To Mull Tolling Standard In Merck Investor Row
• Charles River Laboratories Pays $585M For Drug Research Co.
• Consumers Again Lose Class Cert. Bid In Supple False Ad Suit
• 6 Steps To Becoming A Superior Supervising Attorney
• Fed. Circ. Upholds Invalidity Of Purdue's Sleep Aid Patents
• Top 10 Food And Drug Product Law Developments For 2015
• Get Ready For EU Unified Patent Court And Unitary Patent
• New FDA Guidance Advances Pharma Manufacturing Tech
• Shkreli Barred From Using E-Trade Funds Backing His Bond
• Bayer Says Women Haven't Proved Mirena IUD Caused Injuries
• Life Sciences Group Of The Year: Sidley Austin
• Sanofi Dodges Securities Fraud Class Action In NY
• Abbott, Whistleblower Can't End Stent False Claims Suit
• Deals Rumor Mill: Shire, Oi SA, The Linde Group
• House Passes Bill To Scrub 'Burdensome' Rules
• Judge Cold To Otsuka's Exclusivity Claims In FDA Row
• KaloBios Investors Sue Over Shkreli Arrest
• Intellectual Property Pro Joins Williams Mullen
• Allergan Expands Botox Hold With $90M Biopharma Co. Buy
• Toe Implant Fight Wrongly Sent To State Court, Stryker Says
• Post-Grant Challenges In Life Sciences: 2015 In Review
• 3rd Circ. Told Hangley Represented Nonexistent Co.
• Insurer Must Cover DNA Testing Co. In Privacy Suit
• Depomed, Endo Drop Patent Suit Over Painkiller Opana ER
• Australian Co. Takes Mylan Subsidiary Dispute To Singapore
• 3rd Circ. Won't Revive Ex-Pfizer Workers' Benefits Spat
• Life Sciences Group Of The Year: Irell & Manella LLP
• Apotex Loses Bid To Block Cephalon Experts In Provigil Trial
• House Sends ACA Repeal Bill To White House
• House Debates Bill To Eliminate 'Burdensome' Rules
• $227M In Bank, Biotech Filings Keep IPO Pipeline Gushing
• Hyland's False Ad Suit Always About Fake Drugs, Class Says
• Vitamin C Buyers Say Vodka TM Suit Can't Nix Antitrust Win
• SAC's $10M Class Action Settlement Gets Judge's Initial Nod
• Roche Leads Health Care Startup's $175M Fundraising Round
• NuVasive To Pay Up To $410M For Medical Tech Co. Ellipse
• GSK Faces Whistleblower Suit Claiming Study Mistakes
• Feds Fight Ex-Warner Chilcott Exec's Bid For Witness Info
• Families Say Animal Studies Back Their Claims In Zofran MDL
• LeClairRyan Adds IP Partner From Thompson Coburn
• Adderall Antitrust Class Shouldn't Win Cert., Shire Says
• Philly Risperdal Plaintiff Can't Get New Damages Trial
• Agilent To Pay Enzo $9M To End Patent Infringement Suit
• Colo. Pot Credit Union Loses Bid For Key Account
• Predictions For Anti-Corruption Enforcement This Year
• Life Sciences M&A Market Likely To Stay Hot In 2016
• FDA's Pelvic Mesh Scrutiny May Have Limited Impact In MDL
• Arrowhead Can't Ditch Investor Suit Over Hep B Drug Trial
• 6th Circ. Won't Rethink Orthofix Win In Trade Secrets Row
• Life Sciences Group Of The Year: Gibson Dunn
• Apotex Decries Biosimilar Notice Ruling At Fed. Circ.
• Law360's Pay-For-Delay Cheat Sheet For 2016
• 3rd Circ. Won't Revive Last Hagens Berman Thalidomide Suit
• Shippers Again Ask Judge To Nix AXA's $9M Drug Theft Row
• Generic-Drug Cos. Urge Senate To Fight FDA Approval Delays
• Nashville Pharmacy Co. Settles FCA Suit For Almost $8M
• Zoloft MDL Judge Keeps Focus On Pfizer's Bid To Toss Claims
• Deals Rumor Mill: Dell, Hansoh Pharma, Dalian Wanda
• FDA Warning Wire: Lawsuit Targets Defiant Compounder
• $10M Avandia Fee Fight Correctly Resolved, Justices Told
• 6 Health Cos. Line Up For IPOs In Busy 2016 Start
• Top 10 Health Law Developments In 2015 And What's Ahead
• FTC Can't See Certain Docs In AbbVie Pay-For-Delay Row
• FDA Rejected Warnings Sought In $140M Motrin Case: J&J
• Provigil Antitrust Trial Should Be Postponed, Drug Cos. Say
• Baxalta Inks $1.6B Cancer Drug Option Deal
• Engineering Contractor Leads 2016 Pipeline With $75M IPO
• AbbVie Ups Ante In Biosimilar Battle
• Endocyte Dodges Class Action Over Cancer Drug Claims
• Hagens Berman Blasted For 'Implausible' Claims In Lens MDL
• Deals Rumor Mill: Shire, New World Development, EQT
• Stryker Presses For More TIG Settlement Cash At 6th Circ.
• Profs Weigh In On 3rd Circ. Lipitor Pay-For-Delay Row
• Mylan 'Declared War' On AstraZeneca IP, Fed. Circ. Hears
• O'Melveny Hires Seasoned FDA Attorney For Its DC Office
• Novo Nordisk Hit With Bias, Whistleblower Suit In NJ
• FDA Raises Approval Barrier For Some Pelvic Mesh Devices
• Forced Registration Makes Flimsy Suit, Mylan Tells Fed. Circ.
• 5 Of The Top Drug And Device Developments In 2015
• Purdue Insomnia Patents Wrongly Put To Bed, Fed. Circ. Told
• Life Sciences Group Of The Year: Covington
• KaloBios Can Pay Workers, But Shkreli Barred Money
• Pathway Genomics To Pay $4M In FCA Settlement
• What Your Outside Counsel Doesn't Know About E-Discovery
• This Could Be A Monumental Year For The 340B Program
• What To Expect From State Attorneys General This Year